Editorial: Cancer Prevention: Targeting Premalignant Epithelial Neoplasms in the Era of Cancer Immunotherapy and Vaccines

Front Immunol. 2022 May 24:13:924099. doi: 10.3389/fimmu.2022.924099. eCollection 2022.

Authors

Nicolas Çuburu¹, Olivera J Finn², Sjoerd H Van Der Burg³

Affiliations

¹ Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute (NIH), Bethesda, MA, United States.
² Department of Immunology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.
³ Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.

No abstract available

Keywords: animal model; antigen discovery; immunotherapy; premalignant lesion; tumor microenvironment; vaccine.

Publication types

Editorial
Comment

MeSH terms

Humans
Immunotherapy
Neoplasms, Glandular and Epithelial*
Precancerous Conditions*
Vaccines*

Substances

Vaccines

Grants and funding

R35 CA210039/CA/NCI NIH HHS/United States